[go: up one dir, main page]

MX2015007751A - Anticuerpos anti-gdf15. - Google Patents

Anticuerpos anti-gdf15.

Info

Publication number
MX2015007751A
MX2015007751A MX2015007751A MX2015007751A MX2015007751A MX 2015007751 A MX2015007751 A MX 2015007751A MX 2015007751 A MX2015007751 A MX 2015007751A MX 2015007751 A MX2015007751 A MX 2015007751A MX 2015007751 A MX2015007751 A MX 2015007751A
Authority
MX
Mexico
Prior art keywords
antibodies
gdf15 antibodies
gdf15
human gdf15
bind
Prior art date
Application number
MX2015007751A
Other languages
English (en)
Other versions
MX370720B (es
Inventor
Solly Weiler
Ting Chen
Zhigang Weng
Ailin Bai
Jeno Gyuris
Lorena Lerner
Sandra Abbott
María Isabel Chiu
Qing Liu
Laura Poling
Nianjun Tao
William M Winston
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of MX2015007751A publication Critical patent/MX2015007751A/es
Publication of MX370720B publication Critical patent/MX370720B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan anticuerpos monoclonales que se unen a GDF15 humano e inhiben su actividad. Los anticuerpos pueden utilizarse para tratar la pérdida de peso corporal, incluida la caquexia, asocida con la sobreexpresión de GDF15 humano.
MX2015007751A 2012-12-21 2013-12-20 Anticuerpos anti-gdf15. MX370720B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745508P 2012-12-21 2012-12-21
US201361827325P 2013-05-24 2013-05-24
PCT/US2013/077139 WO2014100689A1 (en) 2012-12-21 2013-12-20 Anti-gdf15 antibodies

Publications (2)

Publication Number Publication Date
MX2015007751A true MX2015007751A (es) 2015-11-30
MX370720B MX370720B (es) 2019-12-20

Family

ID=50069279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007751A MX370720B (es) 2012-12-21 2013-12-20 Anticuerpos anti-gdf15.

Country Status (13)

Country Link
US (6) US9175076B2 (es)
EP (2) EP3689370A1 (es)
JP (3) JP6758832B2 (es)
KR (1) KR102208861B1 (es)
CN (1) CN105073133B (es)
AR (1) AR094271A1 (es)
AU (1) AU2013364133B2 (es)
CA (1) CA2896076C (es)
DK (1) DK2934584T3 (es)
EA (1) EA038645B1 (es)
ES (1) ES2791183T3 (es)
MX (1) MX370720B (es)
WO (1) WO2014100689A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
UA121453C2 (uk) 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся Спосіб одержання фармацевтичної композиції, яка містить антитіло
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
EP3590537A1 (en) 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
JP6758832B2 (ja) * 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
MX369152B (es) 2013-07-31 2019-10-30 Amgen Inc Construcciones del factor de diferenciación de crecimiento 15 (gdf-15).
EP3063543B1 (en) * 2013-10-31 2020-03-11 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
US10682392B2 (en) 2013-11-21 2020-06-16 The Bringham and Women's Hospital, Inc. Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein
CA2943333A1 (en) 2014-03-19 2015-09-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
PL3653644T3 (pl) 2014-03-26 2024-03-04 Julius-Maximilians-Universität Würzburg Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów
MX2016016826A (es) * 2014-06-20 2017-08-28 Aveo Pharmaceuticals Inc Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.
EP3157952B1 (en) 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SG11201700378PA (en) 2014-07-30 2017-02-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US20170202918A1 (en) * 2014-08-01 2017-07-20 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
PL3197493T3 (pl) * 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
US20170290885A1 (en) * 2014-09-30 2017-10-12 Universiteit Gent A method of treating joint disease
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
DK3212226T3 (da) 2014-10-31 2020-06-15 Ngm Biopharmaceuticals Inc Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
JP6227191B1 (ja) 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3286223B8 (en) 2015-04-23 2024-04-03 HaemaLogiX Ltd Kappa myeloma antigen chimeric antigen receptors and uses thereof
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
EA201890850A1 (ru) * 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
WO2017074774A1 (en) * 2015-10-28 2017-05-04 Yale University Humanized anti-dkk2 antibody and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法
SG11201807279QA (en) * 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
SG11201901020RA (en) * 2016-08-05 2019-03-28 Allakos Inc Anti-siglec-7 antibodies for the treatment of cancer
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
JP7134960B2 (ja) * 2016-12-06 2022-09-12 セントビンセンツ ホスピタル シドニー リミテッド 肥満及び摂食障害の治療
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
AU2018304173A1 (en) * 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
AU2019208025A1 (en) * 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
US20210340263A1 (en) * 2018-08-09 2021-11-04 The Wistar Institute Anti-Follicule Stimulating Hormone Receptor Antibodies
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
KR102238927B1 (ko) * 2018-08-30 2021-04-12 서울대학교산학협력단 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도
US20220048995A1 (en) * 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
JP7539902B2 (ja) 2018-10-22 2024-08-26 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
WO2021111636A1 (ja) 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN111393526B (zh) * 2020-03-30 2022-04-12 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
TWI894280B (zh) * 2020-05-26 2025-08-21 南韓商愛思阿爾法數字醫療科技有限公司 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體
JP7495529B2 (ja) * 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
US20240254213A1 (en) * 2020-10-30 2024-08-01 Hideaki Hara Gdf15 modulator for use in inhibition of ocular tissue fibrosis
IL302646A (en) 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
US11845791B2 (en) 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
EP4384545A1 (en) 2021-08-10 2024-06-19 BYOMass Inc. Anti-gdf15 antibodies, compositions and uses thereof
JP2024541933A (ja) 2021-11-02 2024-11-13 ファイザー・インク 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法
EP4452316A1 (en) 2021-12-22 2024-10-30 BYOMass Inc. Targeting gdf15-gfral pathway
KR20240134385A (ko) * 2022-01-26 2024-09-09 윤난 베이야오 그룹 컴파니 리미티드 항-성장 분화 인자 15의 항체 분자 및 그의 응용
US20250326828A1 (en) 2022-05-09 2025-10-23 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies Specifically Recognizing Gdf15 and Uses Thereof
CN116041497A (zh) * 2022-12-22 2023-05-02 杭州贤至生物科技有限公司 一种猫杯状病毒（fcv）重组蛋白单克隆抗体及制备方法
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
WO2025072516A1 (en) * 2023-09-27 2025-04-03 Aveo Pharmaceuticals, Inc. Methods of reducing weight loss using anti-gdf15 antibodies
WO2025146488A1 (en) 2024-01-05 2025-07-10 Catalym Gmbh Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
EP1117805A2 (en) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
DE60032355T2 (de) 1999-05-17 2007-04-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
AU5018201A (en) 2000-04-20 2001-11-07 St Vincents Hospital Sydney Lt Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
WO2004041170A2 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003295424A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US20060188889A1 (en) 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
US7411438B2 (en) 2003-10-10 2008-08-12 That Corporation Low-power integrated-circuit signal processor with wide dynamic range
WO2005092383A1 (ja) 2004-03-26 2005-10-06 Takeda Pharmaceutical Company Limited 呼吸器疾患の予防・治療剤
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
CA2534871C (en) 2006-02-15 2015-08-04 The Ohio State University Research Foundation Three-gene test to differentiate malignant from benign thyroid nodules
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
CA2660691C (en) 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
EP1884777A1 (en) 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
EP2103943A1 (en) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
GB0902793D0 (en) * 2009-02-20 2009-04-08 Univ Gent GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
GB201004739D0 (en) 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
PH12013500974A1 (en) * 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6758832B2 (ja) 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
EP3157952B1 (en) 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
MX2016016826A (es) 2014-06-20 2017-08-28 Aveo Pharmaceuticals Inc Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.

Also Published As

Publication number Publication date
JP2016508984A (ja) 2016-03-24
US10597444B2 (en) 2020-03-24
EP2934584B1 (en) 2020-02-19
US9725505B2 (en) 2017-08-08
US20250277019A1 (en) 2025-09-04
CN105073133B (zh) 2021-04-20
US20140193427A1 (en) 2014-07-10
US20240166734A1 (en) 2024-05-23
EP3689370A1 (en) 2020-08-05
EA201591198A1 (ru) 2015-11-30
KR20150100837A (ko) 2015-09-02
WO2014100689A1 (en) 2014-06-26
US20180142013A1 (en) 2018-05-24
EP2934584A1 (en) 2015-10-28
EA038645B1 (ru) 2021-09-28
US20210101968A1 (en) 2021-04-08
JP2019056018A (ja) 2019-04-11
US9175076B2 (en) 2015-11-03
ES2791183T3 (es) 2020-11-03
JP2021061864A (ja) 2021-04-22
KR102208861B1 (ko) 2021-01-27
CA2896076A1 (en) 2014-06-26
DK2934584T3 (da) 2020-05-18
CN105073133A (zh) 2015-11-18
HK1215670A1 (en) 2016-09-09
MX370720B (es) 2019-12-20
US11725047B2 (en) 2023-08-15
AU2013364133B2 (en) 2018-10-11
AU2013364133A1 (en) 2015-07-16
BR112015014768A2 (pt) 2017-10-10
US20160083465A1 (en) 2016-03-24
JP6758832B2 (ja) 2020-09-30
CA2896076C (en) 2022-12-06
AR094271A1 (es) 2015-07-22
US12258391B2 (en) 2025-03-25

Similar Documents

Publication Publication Date Title
MX2015007751A (es) Anticuerpos anti-gdf15.
PH12012502215A1 (en) Anti-fgfr2 antibodies
MX2013006100A (es) Agente terapeutico que induce citotoxicidad.
IN2015DN02032A (es)
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MY158992A (en) Forms of rifaximin and uses thereof
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
SG10201802982WA (en) Newcastle disease viruses and uses thereof
NZ709059A (en) Immunotherapy with binding agents
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
TW201611843A (en) Methods of treatment with arginine deiminase
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
WO2012006341A3 (en) Anti-ron antibodies
MX360774B (es) Antagonistas de progesterona.
GB201109238D0 (en) Antibodies
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
AU2013342779A8 (en) Anti-ADAM28 antibody for treating cancer

Legal Events

Date Code Title Description
FG Grant or registration